These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15794711)

  • 1. Benefits and risks assessment of simvastatin in familial hypercholesterolaemia.
    Alonso R; Mata N; Mata P
    Expert Opin Drug Saf; 2005 Mar; 4(2):171-81. PubMed ID: 15794711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and risks of simvastatin in patients with familial hypercholesterolaemia.
    Mata P; Alonso R; Badimón J
    Drug Saf; 2003; 26(11):769-86. PubMed ID: 12908847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual effects of lovastatin and simvastatin on urinary mevalonate excretions in patients with familial hypercholesterolemia.
    Pappu AS; Bacon SP; Illingworth DR
    J Lab Clin Med; 2003 Apr; 141(4):250-6. PubMed ID: 12677170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia.
    Heath KE; Gudnason V; Humphries SE; Seed M
    Atherosclerosis; 1999 Mar; 143(1):41-54. PubMed ID: 10208479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation.
    Dirisamer A; Hachemian N; Bucek RA; Wolf F; Reiter M; Widhalm K
    Eur J Pediatr; 2003 Jun; 162(6):421-5. PubMed ID: 12756561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.
    Mol MJ; Erkelens DW; Gevers Leuven JA; Schouten JA; Stalenhoef AF
    Atherosclerosis; 1988 Feb; 69(2-3):131-7. PubMed ID: 3279966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia.
    Couture P; Brun LD; Szots F; Lelièvre M; Gaudet D; Després JP; Simard J; Lupien PJ; Gagné C
    Arterioscler Thromb Vasc Biol; 1998 Jun; 18(6):1007-12. PubMed ID: 9633944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia.
    Raal FJ; Pilcher GJ; Illingworth DR; Pappu AS; Stein EA; Laskarzewski P; Mitchel YB; Melino MR
    Atherosclerosis; 1997 Dec; 135(2):249-56. PubMed ID: 9430375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of Simvastatin on the plasma antioxidant concentrations in patients with hypercholesterolaemia.
    Human JA; Ubbink JB; Jerling JJ; Delport R; Vermaak WJ; Vorster HH; Lagendijk J; Potgieter HC
    Clin Chim Acta; 1997 Jul; 263(1):67-77. PubMed ID: 9247729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry.
    deGoma EM; Ahmad ZS; O'Brien EC; Kindt I; Shrader P; Newman CB; Pokharel Y; Baum SJ; Hemphill LC; Hudgins LC; Ahmed CD; Gidding SS; Duffy D; Neal W; Wilemon K; Roe MT; Rader DJ; Ballantyne CM; Linton MF; Duell PB; Shapiro MD; Moriarty PM; Knowles JW
    Circ Cardiovasc Genet; 2016 Jun; 9(3):240-9. PubMed ID: 27013694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of therapy with simvastatin 80 mg and 120 mg in patients with familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Chik G
    Int J Clin Pract; 2001 Dec; 55(10):673-5. PubMed ID: 11777291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One year experience in the treatment of familial hypercholesterolaemia with simvastatin.
    Quiney J; Watts GF; Kerr-Muir M; Slavin B; Lewis B
    Postgrad Med J; 1992 Jul; 68(801):575-80. PubMed ID: 1437957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose of simvastatin normalizes postprandial remnant-like particle response in patients with heterozygous familial hypercholesterolemia.
    Twickler TB; Dallinga-Thie GM; de Valk HW; Schreuder PC; Jansen H; Cabezas MC; Erkelens DW
    Arterioscler Thromb Vasc Biol; 2000 Nov; 20(11):2422-7. PubMed ID: 11073847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Semra YK; Crook MA
    QJM; 1998 Apr; 91(4):291-4. PubMed ID: 9666952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor.
    Benítez S; Ordóñez-Llanos J; Franco M; Marín C; Paz E; López-Miranda J; Otal C; Pérez-Jiménez F; Sánchez-Quesada JL
    Am J Cardiol; 2004 Feb; 93(4):414-20. PubMed ID: 14969613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
    Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
    Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications.
    Watts GF; Cummings MH; Umpleby M; Quiney JR; Naoumova R; Thompson GR; Sönksen PH
    Eur J Clin Invest; 1995 Aug; 25(8):559-67. PubMed ID: 7589011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
    McCullough PA; Ballantyne CM; Sanganalmath SK; Langslet G; Baum SJ; Shah PK; Koren A; Mandel J; Davidson MH
    Am J Cardiol; 2018 Apr; 121(8):940-948. PubMed ID: 29472008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.